Skip to main content

Table 2 Inclusion criteria

From: Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy

1. Male or female participants 6 to 25 years old at screening visit

2. History of IgE-mediated allergy to at least three foods within the following list: peanut, milk, egg, wheat, oat, soy, barley, rye, buckwheat, hazelnut, pecan, cashew, pistachio, almond, walnut and sesame

3. Participants currently following a strict avoidance of these three foods

4. Positive SPT with a largest wheal diameter ≥ 6 mm to all three foods

5. Food-specific IgE level greater than 15 kU/L for all three foods

6. Positive DBPCFC to treatment food mix with an eliciting dose ≤ 300 mg of total food protein

7. Signed informed consent and assent